World Orphan Drug Congress USA 2017
community download

Download Pursuing Accelerated Approval for Rare Disease Therapeutics

Retrophin at World Orphan Drug Congress USA 2016

Download Alvin's presentation here for more information on:

The Sparsentan Case Study

  • Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
  • Sparsentan–Dual Mechanism of Action
  • SparsentanPhase 2 Study –DUET

Accelerated Approval

  • What is accelerated approval?
  • Success stories: Using AA and biomarkers in rare disease drug development
  • What makes for a good biomarker?
  • Making the case for proteinuria as a surrogate endpoint
  • ETA receptor antagonists have shown reduction of proteinuria in various clinical settings
  • Recent advancements on the regulatory front

Find out more about the regulatory pathways in Orphan Drug Research by joining us at the  World Orphan Drug Congress USA 2017 . For example, we have a fantastic Keynote Panel on  Prescription Drug User Fee Act (PDUFA VI) and 21ST Century Cures – recent and pending legislative efforts to make drugs better for patients.

Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*

Remember my details Information

Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Privacy statement »
Manage your email preferences »

You will be emailed the document as an attachment (1,044Kb in size)